News By Tag
News By Location
DCA and Avemar Show Clinical Promise Against Hormone Resistant Prostate Cancer
As a follow up to a previous reports of DCA and Avemar working against AML Leukemia and CLL Leukemia, a new case has surfaced of the protocol working against Hormone Resistant Prostate Cancer.
"Hormone refractory [(resistant)]
"DCA + Avemar resulted in a PSA drop of about 25% in just 2 weeks!"
– Dr. Akbar Khan, Medicor Cancer Centres
PSA is Prostate-specific antigen. It is a marker for the severity of prostate cancer.
"PSA is present in small quantities in the serum of men with healthy prostates, but is often elevated in the presence of prostate cancer or other prostate disorders."
Here is a link to the case study involving CLL Leukemia:
Here is a link to the case study involving AML Leukemia:
And here is a link to the original video discussing the protocol: